[1]SUBBIAH V, KURZROCK R.Debunking the delusion that precision oncology is an illusion[J].Oncologist, 2017.[Epub ahead of print].
|
[2]BRUIX J, QIN S, MERLE P, et al.Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE) :a randomised, double-blind, placebo-controlled, phase 3 trial[J].Lancet, 2017, 389 (10064) :56-66.
|
[3]IKEDA K, KUDO M, KAWAZOE S, et al.Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma[J].J Gastroenterol, 2017, 52 (4) :512-519.
|
[4]LEE JS.The mutational landscape of hepatocellular carcinoma[J].Clin Mol Hepatol, 2015, 21 (3) :220-229.
|
[5]ZOU S, LI J, ZHOU H, et al.Mutational landscape of intrahepatic cholangiocarcinoma[J].Nat Commun, 2014, 5:5696.
|
[6] MERIC-BERNSTAM F, BRUSCO L, SHAW K, et al.Feasibility of large-scale genomic testing to facilitate enrollment onto genomically matched clinical trials[J].J Clin Oncol, 2015, 33 (25) :2753-2762.
|
[7]PRASAD V.Perspective:the precision-oncology illusion[J].Nature, 2016, 537 (7619) :s63.
|
[8]ABRAHAMS E, ECK SL.Molecular medicine:precision oncology is not an illusion[J].Nature, 2016, 539 (7629) :357.
|
[9]WHELER JJ, JANKU F, NAING A, et al.Cancer therapy directed by comprehensive genomic profiling:a single center study[J].Cancer Res, 2016, 76 (13) :3690-3701.
|
[10]SCHWAEDERLE M, PARKER BA, SCHWAB RB, et al.Precision oncology:the UC San Diego Moores Cancer Center PREDICTexperience[J].Mol Cancer Ther, 2016, 15 (4) :743-752.
|